Intermittent hypoxia is a key regulator of cancer cell and endothelial cell interplay in tumours

FEBS Journal

Volumn 275, Issue 12, 2008, Pages 2991-3002

  Toffoli, S ^a   Michiels, C ^a  

^a UNIVERSITY OF NAMUR   (Belgium)

Author keywords

Apoptosis; Cancer; Chemoresistance; Endothelial cell; Hypoxia inducible factor 1; Intermittent hypoxia; Radioresistance; Reactive oxygen species; Reoxygenation; Tumor cell

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA;

CANCER CELL; CARCINOGENESIS; CHRONIC HYPOXIA; ENDOTHELIUM CELL; HUMAN; HYPOXIA; INTERMITTENT HYPOXIA; NONHUMAN; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; TUMOR RESISTANCE; TUMOR VASCULARIZATION;

ANIMALS; CELL HYPOXIA; CELL SURVIVAL; ENDOTHELIAL CELLS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MICE; NEOPLASMS; TRANSCRIPTION, GENETIC;

EID: 44349151470     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/j.1742-4658.2008.06454.x     Document Type: Review

References (101)

1. Brown JM (1990) Tumor hypoxia, drug resistance, and metastases. J Natl Cancer Inst 82, 338 339.
2. Thomlinson RH Gray LH (1955) The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer 9, 539 549.
3. Brown JM (1979) Evidence for acutely hypoxic cells in mouse tumours, and a possible mechanism of reoxygenation. Br J Radiol 52, 650 656.
4. Chaplin DJ, Durand RE Olive PL (1986) Acute hypoxia in tumors: implications for modifiers of radiation effects. Int J Radiat Oncol Biol Phys 12, 1279 1282.
5. Chaplin DJ, Olive PL Durand RE (1987) Intermittent blood flow in a murine tumor: radiobiological effects. Cancer Res 47, 597 601.
6. Bergers G Benjamin LE (2003) Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3, 401 410.
7. Morikawa S, Baluk P, Kaidoh T, Haskell A, Jain RK McDonald DM (2002) Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am J Pathol 160, 985 1000.
8. Padera TP, Stoll BR, Tooredman JB, Capen D, di Tomaso E Jain RK (2004) Pathology: cancer cells compress intratumour vessels. Nature 427, 695.
9. Baudelet C, Cron GO, Ansiaux R, Crokart N, DeWever J, Feron O Gallez B (2006) The role of vessel maturation and vessel functionality in spontaneous fluctuations of T2*-weighted GRE signal within tumors. NMR Biomed 19, 69 76.
10. Chaplin DJ Hill SA (1995) Temporal heterogeneity in microregional erythrocyte flux in experimental solid tumours. Br J Cancer 71, 1210 1213.
11. Bennewith KL Durand RE (2004) Quantifying transient hypoxia in human tumor xenografts by flow cytometry. Cancer Res 64, 6183 6189.
12. Braun RD, Lanzen JL Dewhirst MW (1999) Fourier analysis of fluctuations of oxygen tension and blood flow in R3230Ac tumors and muscle in rats. Am J Physiol 277, H551 H568.
13. Hill SA, Pigott KH, Saunders MI, Powell ME, Arnold S, Obeid A, Ward G, Leahy M, Hoskin PJ Chaplin DJ (1996) Microregional blood flow in murine and human tumours assessed using laser Doppler microprobes. Br J Cancer Suppl 27, S260 S263.
14. Pigott KH, Hill SA, Chaplin DJ Saunders MI (1996) Microregional fluctuations in perfusion within human tumours detected using laser Doppler flowmetry. Radiother Oncol 40, 45 50.
15. Cairns RA, Kalliomaki T Hill RP (2001) Acute (cyclic) hypoxia enhances spontaneous metastasis of KHT murine tumors. Cancer Res 61, 8903 8908.
16. Cardenas-Navia LI, Yu D, Braun RD, Brizel DM, Secomb TW Dewhirst MW (2004) Tumor-dependent kinetics of partial pressure of oxygen fluctuations during air and oxygen breathing. Cancer Res 64, 6010 6017.
17. Nordsmark M, Bentzen SM Overgaard J (1994) Measurement of human tumour oxygenation status by a polarographic needle electrode. An analysis of inter- and intratumour heterogeneity. Acta Oncol 33, 383 389.
18. Foo SS, Abbott DF, Lawrentschuk N Scott AM (2004) Functional imaging of intratumoral hypoxia. Mol Imaging Biol 6, 291 305.
19. Nozue M, Lee I, Yuan F, Teicher BA, Brizel DM, Dewhirst MW, Milross CG, Milas L, Song CW, Thomas CD et al. (1997) Interlaboratory variation in oxygen tension measurement by Eppendorf 'Histograph' and comparison with hypoxic marker. J Surg Oncol 66, 30 38.
20. Jakobsson A Nilsson GE (1993) Prediction of sampling depth and photon pathlength in laser Doppler flowmetry. Med Biol Eng Comput 31, 301 307.
21. Nilsson GE, Tenland T Oberg PA (1980) Evaluation of a laser Doppler flowmeter for measurement of tissue blood flow. IEEE Trans Biomed Eng 27, 597 604.
22. Ljungkvist AS, Bussink J, Kaanders JH van der Kogel AJ (2007) Dynamics of tumor hypoxia measured with bioreductive hypoxic cell markers. Radiat Res 167, 127 145.
23. Padhani AR, Krohn KA, Lewis JS Alber M (2007) Imaging oxygenation of human tumours. Eur Radiol 17, 861 872.
24. Gallez B, Baudelet C Jordan BF (2004) Assessment of tumor oxygenation by electron paramagnetic resonance: principles and applications. NMR Biomed 17, 240 262.
25. Landuyt W, Hermans R, Bosmans H, Sunaert S, Beatse E, Farina D, Meijerink M, Zhang H, Van Den Bogaert W, Lambin P et al. (2001) BOLD contrast fMRI of whole rodent tumour during air or carbogen breathing using echo-planar imaging at 1.5 T. Eur Radiol 11, 2332 2340.
26. Ogawa S, Lee TM, Kay AR Tank DW (1990) Brain magnetic resonance imaging with contrast dependent on blood oxygenation. Proc Natl Acad Sci USA 87, 9868 9872.
27. Mahy P, De Bast M, Gallez B, Gueulette J, Koch CJ, Scalliet P Gregoire V (2003) In vivo colocalization of 2-nitroimidazole EF5 fluorescence intensity and electron paramagnetic resonance oximetry in mouse tumors. Radiother Oncol 67, 53 61.
28. Dewhirst MW, Braun RD Lanzen JL (1998) Temporal changes in PO2 of R3230AC tumors in Fischer-344 rats. Int J Radiat Oncol Biol Phys 42, 723 726.
29. Ljungkvist AS, Bussink J, Rijken PF, Raleigh JA, Denekamp J Van Der Kogel AJ (2000) Changes in tumor hypoxia measured with a double hypoxic marker technique. Int J Radiat Oncol Biol Phys 48, 1529 1538.
30. Rijken PF, Bernsen HJ, Peters JP, Hodgkiss RJ, Raleigh JA van der Kogel AJ (2000) Spatial relationship between hypoxia and the (perfused) vascular network in a human glioma xenograft: a quantitative multi-parameter analysis. Int J Radiat Oncol Biol Phys 48, 571 582.
31. Arteel GE, Thurman RG Raleigh JA (1998) Reductive metabolism of the hypoxia marker pimonidazole is regulated by oxygen tension independent of the pyridine nucleotide redox state. Eur J Biochem 253, 743 750.
32. Joseph P, Jaiswal AK, Stobbe CC Chapman JD (1994) The role of specific reductases in the intracellular activation and binding of 2-nitroimidazoles. Int J Radiat Oncol Biol Phys 29, 351 355.
33. Melo T, Ballinger JR Rauth AM (2000) Role of NADPH:cytochrome P450 reductase in the hypoxic accumulation and metabolism of BRU59-21, a technetium-99m-nitroimidazole for imaging tumor hypoxia. Biochem Pharmacol 60, 625 634.
34. Saleem A, Charnley N Price P (2006) Clinical molecular imaging with positron emission tomography. Eur J Cancer 42, 1720 1727.
35. Koh WJ, Bergman KS, Rasey JS, Peterson LM, Evans ML, Graham MM, Grierson JR, Lindsley KL, Lewellen TK, Krohn KA et al. (1995) Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using [F-18]fluoromisonidazole positron emission tomography. Int J Radiat Oncol Biol Phys 33, 391 398.
36. Chi JT, Wang Z, Nuyten DS, Rodriguez EH, Schaner ME, Salim A, Wang Y, Kristensen GB, Helland A, Borresen-Dale AL et al. (2006) Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS Med 3, e47.
37. Wang GL, Jiang BH, Rue EA Semenza GL (1995) Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 92, 5510 5514.
38. Wang GL Semenza GL (1995) Purification and characterization of hypoxia-inducible factor 1. J Biol Chem 270, 1230 1237.
39. Salceda S Caro J (1997) Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. J Biol Chem 272, 22642 22647.
40. Semenza GL (2001) HIF-1, O(2), and the 3 PHDs: how animal cells signal hypoxia to the nucleus. Cell 107, 1 3.
41. Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M, Salic A, Asara JM, Lane WS Kaelin WG Jr (2001) HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 292, 464 468.
42. Cockman ME, Masson N, Mole DR, Jaakkola P, Chang GW, Clifford SC, Maher ER, Pugh CW, Ratcliffe PJ Maxwell PH (2000) Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem 275, 25733 25741.
43. Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, Kriegsheim A, Hebestreit HF, Mukherji M, Schofield CJ et al. (2001) Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292, 468 472.
44. Jewell UR, Kvietikova I, Scheid A, Bauer C, Wenger RH Gassmann M (2001) Induction of HIF-1alpha in response to hypoxia is instantaneous. FASEB J 15, 1312 1314.
45. Jiang BH, Rue E, Wang GL, Roe R Semenza GL (1996) Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1. J Biol Chem 271, 17771 17778.
46. Wenger RH (2000) Mammalian oxygen sensing, signalling and gene regulation. J Exp Biol 203, 1253 1263.
47. 2+/calmodulin kinase-dependent activation of hypoxia inducible factor 1 transcriptional activity in cells subjected to intermittent hypoxia. J Biol Chem 280, 4321 4328.
48. Berra E, Richard DE, Gothie E Pouyssegur J (2001) HIF-1-dependent transcriptional activity is required for oxygen-mediated HIF-1alpha degradation. FEBS Lett 491, 85 90.
49. Martinive P, Defresne F, Bouzin C, Saliez J, Lair F, Gregoire V, Michiels C, Dessy C Feron O (2006) Preconditioning of the tumor vasculature and tumor cells by intermittent hypoxia: implications for anticancer therapies. Cancer Res 66, 11736 11744.
50. Toffoli S, Feron O, Raes M Michiels C (2007) Intermittent hypoxia changes HIF-1alpha phosphorylation pattern in endothelial cells: unravelling of a new PKA-dependent regulation of HIF-1alpha. Biochim Biophys Acta 1773, 1558 1571.
51. Mottet D, Dumont V, Deccache Y, Demazy C, Ninane N, Raes M Michiels C (2003) Regulation of hypoxia-inducible factor-1alpha protein level during hypoxic conditions by the phosphatidylinositol 3-kinase/Akt/glycogen synthase kinase 3beta pathway in HepG2 cells. J Biol Chem 278, 31277 31285.
52. Minet E, Arnould T, Michel G, Roland I, Mottet D, Raes M, Remacle J Michiels C (2000) ERK activation upon hypoxia: involvement in HIF-1 activation. FEBS Lett 468, 53 58.
53. Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW Giaccia AJ (1996) Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 379, 88 91.
54. Cosse JP, Sermeus A, Vannuvel K, Ninane N, Raes M Michiels C (2007) Differential effects of hypoxia on etoposide-induced apoptosis according to the cancer cell lines. Mol Cancer 6, 61 76.
55. Lee SM, Lee CT, Kim YW, Han SK, Shim YS Yoo CG (2006) Hypoxia confers protection against apoptosis via PI3K/Akt and ERK pathways in lung cancer cells. Cancer Lett 242, 231 238.
56. Merighi S, Benini A, Mirandola P, Gessi S, Varani K, Leung E, Maclennan S, Baraldi PG Borea PA (2007) Hypoxia inhibits paclitaxel-induced apoptosis through adenosine-mediated phosphorylation of bad in glioblastoma cells. Mol Pharmacol 72, 162 172.
57. Moeller BJ, Richardson RA Dewhirst MW (2007) Hypoxia and radiotherapy: opportunities for improved outcomes in cancer treatment. Cancer Metastasis Rev 26, 241 248.
58. Piret JP, Lecocq C, Toffoli S, Ninane N, Raes M Michiels C (2004) Hypoxia and CoCl2 protect HepG2 cells against serum deprivation- and t-BHP-induced apoptosis: a possible anti-apoptotic role for HIF-1. Exp Cell Res 295, 340 349.
59. Schnitzer SE, Schmid T, Zhou J Brune B (2006) Hypoxia and HIF-1alpha protect A549 cells from drug-induced apoptosis. Cell Death Differ 13, 1611 1613.
60. Song X, Liu X, Chi W, Liu Y, Wei L, Wang X Yu J (2006) Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1alpha gene. Cancer Chemother Pharmacol 58, 776 784.
61. Dong Z Wang J (2004) Hypoxia selection of death-resistant cells. A role for Bcl-X(L). J Biol Chem 279, 9215 9221.
62. Durand RE Aquino-Parsons C (2001) Non-constant tumour blood flow - implications for therapy. Acta Oncol 40, 862 869.
63. Reynolds TY, Rockwell S Glazer PM (1996) Genetic instability induced by the tumor microenvironment. Cancer Res 56, 5754 5757.
64. Cheng KC, Cahill DS, Kasai H, Nishimura S Loeb LA (1992) 8-Hydroxyguanine, an abundant form of oxidative DNA damage, causes G - - T and A - - C substitutions. J Biol Chem 267, 166 172.
65. Matthews CP, Colburn NH Young MR (2007) AP-1 a target for cancer prevention. Curr Cancer Drug Targets 7, 317 324.
66. Yuan G, Adhikary G, McCormick AA, Holcroft JJ, Kumar GK Prabhakar NR (2004) Role of oxidative stress in intermittent hypoxia-induced immediate early gene activation in rat PC12 cells. J Physiol 557, 773 783.
67. Shaulian E Karin M (2001) AP-1 in cell proliferation and survival. Oncogene 20, 2390 2400.
68. Eferl R Wagner EF (2003) AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer 3, 859 868.
69. Gloire G, Legrand-Poels S Piette J (2006) NF-kappaB activation by reactive oxygen species: fifteen years later. Biochem Pharmacol 72, 1493 1505.
70. Prabhakar NR (2001) Oxygen sensing during intermittent hypoxia: cellular and molecular mechanisms. J Appl Physiol 90, 1986 1994.
71. Ryan S, McNicholas WT Taylor CT (2007) A critical role for p38 map kinase in NF-kappaB signaling during intermittent hypoxia/reoxygenation. Biochem Biophys Res Commun 355, 728 733.
72. Hayakawa M, Miyashita H, Sakamoto I, Kitagawa M, Tanaka H, Yasuda H, Karin M Kikugawa K (2003) Evidence that reactive oxygen species do not mediate NF-kappaB activation. EMBO J 22, 3356 3366.
73. Yang J, Su Y Richmond A (2007) Antioxidants tiron and N-acetyl-L-cysteine differentially mediate apoptosis in melanoma cells via a reactive oxygen species-independent NF-kappaB pathway. Free Radic Biol Med 42, 1369 1380.
74. Qanungo S, Wang M Nieminen AL (2004) N-Acetyl-L-cysteine enhances apoptosis through inhibition of nuclear factor-kappaB in hypoxic murine embryonic fibroblasts. J Biol Chem 279, 50455 50464.
75. Bond M, Fabunmi RP, Baker AH Newby AC (1998) Synergistic upregulation of metalloproteinase-9 by growth factors and inflammatory cytokines: an absolute requirement for transcription factor NF-kappa B. FEBS Lett 435, 29 34.
76. Guttridge DC, Albanese C, Reuther JY, Pestell RG Baldwin AS Jr (1999) NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol 19, 5785 5799.
77. Huang S, Robinson JB, Deguzman A, Bucana CD Fidler IJ (2000) Blockade of nuclear factor-kappaB signaling inhibits angiogenesis and tumorigenicity of human ovarian cancer cells by suppressing expression of vascular endothelial growth factor and interleukin 8. Cancer Res 60, 5334 5339.
78. Karin M, Cao Y, Greten FR Li ZW (2002) NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2, 301 310.
79. Kim DW, Sovak MA, Zanieski G, Nonet G, Romieu-Mourez R, Lau AW, Hafer LJ, Yaswen P, Stampfer M, Rogers AE et al. (2000) Activation of NF-kappaB/Rel occurs early during neoplastic transformation of mammary cells. Carcinogenesis 21, 871 879.
80. Rayet B Gelinas C (1999) Aberrant rel/nfkb genes and activity in human cancer. Oncogene 18, 6938 6947.
81. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL Simons JW (1999) Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 59, 5830 5835.
82. Kietzmann T Gorlach A (2005) Reactive oxygen species in the control of hypoxia-inducible factor-mediated gene expression. Semin Cell Dev Biol 16, 474 486.
83. Moeller BJ, Cao Y, Li CY Dewhirst MW (2004) Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell 5, 429 441.
84. Vordermark D, Shibata T Brown JM (2001) Green fluorescent protein is a suitable reporter of tumor hypoxia despite an oxygen requirement for chromophore formation. Neoplasia 3, 527 534.
85. Brem S, Brem H, Folkman J, Finkelstein D Patz A (1976) Prolonged tumor dormancy by prevention of neovascularization in the vitreous. Cancer Res 36, 2807 2812.
86. Folkman J (2003) Angiogenesis and apoptosis. Semin Cancer Biol 13, 159 167.
87. Gimbrone MA Jr, Leapman SB, Cotran RS Folkman J (1972) Tumor dormancy in vivo by prevention of neovascularization. J Exp Med 136, 261 276.
88. Holmgren L, O'Reilly MS Folkman J (1995) Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1, 149 153.
89. Folkman J Kalluri R (2004) Cancer without disease. Nature 427, 787.
90. Wood JM, Bold G, Buchdunger E, Cozens R, Ferrari S, Frei J, Hofmann F, Mestan J, Mett H, O'Reilly T et al. (2000) PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 60, 2178 2189.
91. Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, Chung DC, Sahani DV, Kalva SP, Kozin SV et al. (2004) Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10, 145 147.
92. Goto H, Yano S, Matsumori Y, Ogawa H, Blakey DC Sone S (2004) Sensitization of tumor-associated endothelial cell apoptosis by the novel vascular-targeting agent ZD6126 in combination with cisplatin. Clin Cancer Res 10, 7671 7676.
93. Folkman J (2002) Looking for a good endothelial address. Cancer Cell 1, 113 115.
94. Baguley BC, Holdaway KM, Thomsen LL, Zhuang L Zwi LJ (1991) Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: evidence for a vascular mechanism. Eur J Cancer 27, 482 487.
95. Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O'Reilly MS Folkman J (2000) Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60, 1878 1886.
96. Hobson B Denekamp J (1984) Endothelial proliferation in tumours and normal tissues: continuous labelling studies. Br J Cancer 49, 405 413.
97. St Croix B, Rago C, Velculescu V, Traverso G, Romans KE, Montgomery E, Lal A, Riggins GJ, Lengauer C, Vogelstein B et al. (2000) Genes expressed in human tumor endothelium. Science 289, 1197 1202.
98. Hewett P, Popplewell A, Finney H Murray JC (1999) Changes in microvessel endothelial cell gene expression in an in vitro human breast tumour endothelial cell model. Angiogenesis 3, 221 229.
99. Lu C, Bonome T, Li Y, Kamat AA, Han LY, Schmandt R, Coleman RL, Gershenson DM, Jaffe RB, Birrer MJ et al. (2007) Gene alterations identified by expression profiling in tumor-associated endothelial cells from invasive ovarian carcinoma. Cancer Res 67, 1757 1768.
100. Gorski DH, Beckett MA, Jaskowiak NT, Calvin DP, Mauceri HJ, Salloum RM, Seetharam S, Koons A, Hari DM, Kufe DW et al. (1999) Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 59, 3374 3378.
101. Kanaan A, Farahani R, Douglas RM, Lamanna JC Haddad GG (2006) Effect of chronic continuous or intermittent hypoxia and reoxygenation on cerebral capillary density and myelination. Am J Physiol Regul Integr Comp Physiol 290, R1105 R1114.